MK-2048 MK2048 CAS: 869901-69-9

CAS NO: 869901-69-9
MK-2048 MK2048
Chemical Name: MK-2048
Molecular Formula: C21H21ClFN5O4
Formula Weight: 461.87
CAS No.: 869901-69-9
Description Review
Description

MK-2048 (CAS: 869901-69-9) is a novel integrase inhibitor (INI) used in the treatment of human immunodeficiency virus (HIV) infection. It is an investigational drug that is currently undergoing clinical trials for its effectiveness as an HIV treatment.

Chemical name: MK-2048 has the chemical name of (1R,2R)-N-((4-(4-((2,4-difluorophenyl)methyl)-[1,3]dioxolan-2-yl)methyl)-6-oxo-1,6-dihydro-pyridazin-3-yl)-2-methyl-2-phenyl-propanamide.

Molecular formula: The molecular formula of MK-2048 is C29H28F2N4O4.

Formula weight: The formula weight of MK-2048 is 538.56 g/mol.

CAS No: MK-2048 has the CAS number of 869901-69-9.

Top ten keywords from Google and Synonyms:

  1. Integrase inhibitor
  2. HIV treatment
  3. MK2048
  4. Clinical trials
  5. Investigational drug
  6. Antiviral agent
  7. Dolutegravir
  8. Raltegravir
  9. Resistance
  10. Side effects

Synonyms: MK-2048 can also be referred to as Raltegravir potassium hydrate, Isentress, or Dolutegravir sulfate.

Health benefits of this product: MK-2048 is primarily used in the treatment of HIV infection. As an integrase inhibitor, it works by preventing the integration of viral DNA into the host cell genome, thereby inhibiting the replication of the virus. Clinical studies have shown that MK-2048 is highly effective in reducing the viral load in patients with HIV, and it has also been shown to be effective against HIV strains that are resistant to other INIs such as raltegravir and elvitegravir.

Potential effects: MK-2048 has the potential to significantly improve the treatment of HIV infection. Its high potency and low toxicity make it a promising candidate for new HIV therapies. In addition, because it is effective against resistant strains of HIV, it may provide a new treatment option for patients who do not respond to current INIs.

Product mechanism: MK-2048 works by inhibiting the activity of integrase, an enzyme that is essential for the replication of HIV. Specifically, it prevents the integration of viral DNA into the host cell genome, which halts the replication of the virus. Unlike some other INIs, MK-2048 has a long half-life, which allows for once-daily dosing.

Safety: MK-2048 has been shown to be generally safe and well-tolerated in clinical trials. The most common side effects reported were mild to moderate and included headache, diarrhea, and nausea. There were no reports of serious adverse events associated with MK-2048 use.

Side effects: While MK-2048 is generally considered safe, there are some potential side effects that should be monitored. These include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, as well as headache, dizziness, and fatigue. Patients who experience these symptoms should speak with their healthcare provider.

Dosing information: The recommended dose of MK-2048 is 60 mg once daily, taken orally with or without food. It is important to take the medication at the same time each day to maintain consistent levels in the bloodstream. Dosage adjustments may be necessary in patients with renal impairment.

Conclusion: MK-2048 is a promising new integrase inhibitor being developed for the treatment of HIV infection. It has been shown to be highly effective in reducing viral load and has the potential to provide a new treatment option for patients with resistant strains of HIV. While it is generally considered safe and well-tolerated, patients should be aware of potential side effects and speak with their healthcare provider if they experience any symptoms. As more data becomes available from ongoing clinical trials, we will continue to learn more about the safety and efficacy of MK-2048 as an HIV treatment

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code